Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.
about
Immune complexes as therapy for autoimmunityInduction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate ImmunityRhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)The pathogenesis of immune thrombocytopaenic purpuraReactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.Anti-RhD immunoglobulin in the treatment of immune thrombocytopeniaManagement of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principlePlatelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.Comparison of cytokine responses with anti-d and intravenous immunoglobulin in idiopathic thrombocytopenia.A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) productionAntibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics.Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions.Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.Chemical treatment of anti-D results in improved efficacy for the inhibition of Fcgamma receptor-mediated phagocytosis.Monoclonal versus polyclonal anti-D in the treatment of ITP.Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells.
P2860
Q24558642-3135B5CA-F7E5-4EF2-8852-46D99597DD3FQ26781290-91338E81-8519-4D87-9B62-DEB8C0CA8142Q26824798-F7474245-BDE1-443A-B10B-116EBDE7016AQ28236898-CD258AA1-1EA6-4EAD-9A4F-258744503AE1Q33368580-537D2863-5F22-4247-98D2-6E1F1A4F185BQ33373425-5124474C-5884-44D2-9D80-F40323E8EBC2Q33374445-380B5920-9442-45CD-9DCF-013563F85A82Q33385974-B5C7A1E7-4AC3-450D-869F-353B738BC570Q33390001-8B54BD82-4D0C-495F-8EB7-0A979E62224CQ33394438-DC438835-98FD-4E95-8A94-6BA1D4308850Q33401630-FD7DB309-FEF3-4083-9BCC-A977B76C012DQ33407453-F723A5E8-57E8-4EB6-9EE5-A7B58F708ABFQ33420988-D99168D1-C5BD-42F6-A8ED-BF3B598F4D8CQ34170859-4F891775-943A-4917-ACD9-812000EA0840Q36755847-FEC7B26D-39E0-4E03-8F7A-DF87458312A5Q36787544-6AE2F65A-D624-4E53-B8C2-09CFDCEEF15AQ37252443-07B17AE5-ED82-4E42-8246-A26EFA134261Q40090644-EED9E015-C1B3-4024-81E3-8ACE70B7F188Q46321417-C86B1957-D30F-4DF7-AEA9-C34002393494Q46933780-D08AE5F5-87A5-41F6-8FEB-42C18E85AF76
P2860
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@ast
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@en
type
label
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@ast
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@en
prefLabel
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@ast
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@en
P2093
P2860
P1476
Intravenous (IV) anti-D and IV ...... nd FcgammaRIIIa polymorphisms.
@en
P2093
B M R Woloski
Howard B Fleit
Marion E Reid
Martin L Lesser
Masja Haas
Nancy M Heddle
Nichola Cooper
P2860
P304
P356
10.1111/J.1365-2141.2004.04804.X
P407
P577
2004-02-01T00:00:00Z